Global pharmaceutical companies have significantly ramped up their investments in partnerships with Chinese biotechs, surpassing $48.5 billion in the first half of 2025 alone. This staggering amount has already exceeded the total investment made in the entire year of 2024, showcasing the growing trend of collaboration between multinational pharmaceutical companies and Chinese biotech firms. The analysis by IQVIA indicates a promising trajectory, with expectations that the deal volume for 2025 will easily surpass the 100 agreements signed in the previous year.
In recent years, there has been a noticeable shift in the willingness of global biopharma companies to engage in partnerships with Chinese-originated therapies. This strategic move allows these companies to tap into efficient and cost-effective innovation while providing Chinese firms with global validation for their novel assets and technologies. Moreover, these collaborations ensure a steady cash flow to support further development, fostering a mutually beneficial relationship in the biopharma landscape.
The first half of 2025 witnessed a total of 61 partnership deals signed with Chinese biotechs, out of which 37 involved U.S.-based companies on the other end. This indicates a significant increase in the participation of U.S. companies, representing 61% of the deals compared to 37% in 2024. Notably, several deals in the first half of 2025 involved substantial financial transactions, with 16 deals exceeding $1 billion in value. This highlights the growing confidence and commitment of pharmaceutical companies towards collaborations in China.
Oncology emerged as the predominant therapeutic area in these partnership deals, aligning with a consistent trend observed over the years. Additionally, fields such as immunological and inflammatory diseases are also witnessing a rise in collaborative efforts between global pharmaceutical giants and Chinese biotechs. The strategic alliances forged in the first half of 2025 reflect a shift towards backloaded deals, where pharma companies leverage early-stage research conducted by Chinese biotechs to de-risk investments before further financial commitments.
Notable examples include Pfizer’s significant investment in 3SBio, amounting to $1.25 billion upfront with additional milestones, granting access to a promising bispecific antibody targeting PD-1 and VEGF for various cancers. AstraZeneca also engaged in multiple deals, offering substantial deal value to Harbour BioMed for multi-specific antibodies in immunology and oncology. Despite concerns regarding geopolitical influences on such partnerships, IQVIA remains optimistic about the continued growth and success of cross-border collaborations in the biopharma sector.
Former FDA commissioner Scott Gottlieb highlighted the importance of retaining the biomedical edge in the U.S. amidst China’s rapid advancements in the sector. Emphasizing the critical need to prevent a technological disadvantage, Gottlieb’s warning underscores the significance of strategic collaborations and investments to ensure the continued innovation and leadership of the U.S. biopharma industry. The evolving landscape of biopharma investments in China not only reflects a shift towards global innovation but also underscores the strategic imperatives for sustained growth and competitiveness in the pharmaceutical sector.
- The biopharma sector witnessed a substantial increase in investments, with over $48.5 billion committed to partnerships in China in the first half of 2025, surpassing the total investment in 2024.
- Collaboration between global pharmaceutical companies and Chinese biotechs is on the rise, driven by the quest for efficient innovation and global validation of novel assets and technologies.
- Oncology remains a key focus area for partnership deals, signaling continued interest in advancing treatments for cancer and other therapeutic areas.
- Strategic investments and alliances in China reflect a shift towards backloaded deals, emphasizing the importance of de-risking investments before further commitments.
Tags: biopharma
Read more on biospace.com